Growth continuity tested amid factory capacity constraints
Relaxo reports Q2 results on Nov 13 with the Street watching whether 7-8% revenue growth can persist despite ongoing factory renovation and reduced manufacturing capacity. Margins and volume momentum are the key gauges.
Relaxo Footwears reports Q2 FY27 results on November 13 after delivering a solid start to the fiscal year. In Q1 (ended Jun 2026), revenue grew 7.7% YoY to ₹705 crores with net profit rising 12.4% to ₹54.94 crores. The full-year FY2027 guidance implies 10.4% revenue growth and 16.7% EPS expansion. But Q2 arrives against a backdrop of factory modernization—the company in August reassessed total manufacturing capacity down to 9.1 lakh pairs per day from 10.5 lakh, citing ongoing reconstruction of older plants. The Street's focus will be on whether Relaxo can sustain mid-single-digit growth momentum and defend margins as utilization pressure persists.
The on-plan expectation
~₹700–750 Cr
to sustain +7 to +8% YoY growth; Q1 was ₹705 Cr, so flat to mid-single digit momentum indicates on-track
~8–9%
Q1 EBITDA rose 8.8% YoY; key watch is whether lower capacity utilization pressures margin %
Watch
Q1 net profit +12.4%, outpacing revenue +7.7%; sustainability amid capex and lower capacity is the swing factor
A strong Q2 print would show revenue growth >8% with EBITDA margins stable or improved despite the capacity headwind—evidence that pricing power and cost control offset lower utilization. A weak print would be revenue growth 100 bps, signaling that demand is softer than the full-year guidance implies or that capex-related disruption is heavier than guided.
On track with guidance?
Yes, if growth stays near 7–8% for Q2. Q1's 7.7% implies momentum—even with factory renovation headwinds, management's 10.4% full-year growth target hinges on Q3–Q4 acceleration once capacity ramp resumes. The capacity reassessment down (not up) is the risk signal: if demand softens, lower utilization becomes a drag. If demand is robust, Relaxo should be able to boost production once the renovation completes, driving back-half acceleration and reaching full-year guidance. Analysts are pricing in 10–11% growth; Q2 will test whether that's real.
What the Street says
Since last quarter: filings and corporate actions
Oct 23
26% stake in Clean Max MUOI (renewable energy SPV)
Strategic pivot to ESG / renewable energy; capital deployment shift; longer-term margin upside if renewable costs decline
Oct 5
Energy Supply & Investment Agreement with Clean Max
Caps energy costs over medium term; supporting margin defense amid inflationary pressures
Sep 30
CS & Compliance Officer Ankit Jain resigned
Routine mgmt transition; no governance red flags; successor TBD
Aug 31
42nd AGM (Sep 24), Annual Report filed; BRSR filed for FY26
Routine governance; no material changes flagged in shareholding or board composition
Aug 13
Capacity reassessment: 10.5L → 9.1L pairs/day
Factory renovation/modernization; near-term capacity headwind; medium-term upside if capex drives productivity
No material insider/promoter activity or pledges flagged. Ownership remains stable: FII 3.11%, DII 9.67%, promoter 71.27% (as of Q1 FY27). The renewable energy investment is strategic, not a distress capital-raise. The capacity reduction is temporary and deliberate—not a demand collapse—so long as the Q2 revenue trajectory holds.
What to watch on result day
1 · Revenue growth momentum
Can Relaxo sustain >7% YoY growth with 9.1L pairs/day capacity? If Q2 revenue is ₹700–750 Cr (on-plan), it validates the 10.4% full-year guidance. If <₹680 Cr, watch management's commentary on demand and back-half acceleration.
2 · EBITDA margin
The critical line. Q1 EBITDA margin (~14% implied) should be defended or improved in Q2. Expansion >100 bps would signal pricing power and cost discipline; contraction >100 bps would raise questions about demand softness or capex cost overruns.
3 · Capacity ramp and capex guidance
Management must clarify the factory renovation timeline and expected capacity recovery. If capex is ramping to ₹50+ Cr/quarter, FCF could face pressure through FY27 even if bottom-line growth accelerates. Watch for updates on when 10.5L pairs/day capacity returns.
Relaxo's Q2 is a test of growth durability amid self-imposed capacity constraints and a macro slowdown in consumer discretionary demand. The company delivered solid Q1 momentum (7.7% growth, margin resilience), and the Street's 10.4% full-year estimate implies confidence in back-half recovery. But the capacity reduction, while temporary, leaves no room for demand disappointment—Q2 revenue must stay in the ₹700–750 Cr band and margins must hold to validate guidance. Promoter control (71.27%) and the renewable energy pivot suggest management confidence in the medium-term narrative (lower energy costs, productivity capex). Watch the absolute revenue number, EBITDA margin trends, and any color on when full capacity returns.
Relaxo Q2 FY27: PAT +2% YoY to ₹36.95 Cr, standalone, as margins compress missing OPM goal
PAT +2.18% YoY · revenue +11.63% · margins compressing · miss vs street
₹701.62 Cr
+11.63% YoY
₹36.95 Cr
+2.18% YoY
5.17%
-0.5pp YoY
₹1.48
Relaxo's standalone PAT rose just 2.2% YoY to ₹36.95 Cr even as revenue from operations grew a healthier 11.6% YoY to ₹701.62 Cr — profit growth trailing topline growth by a wide margin, the hallmark of margin compression rather than demand weakness. Operating margin (EBITDA excl. other income/revenue) fell to 12.15% from 12.91% a year ago, and net margin slipped to 5.27% from 5.64%. Sequentially, revenue was flat-to-down 0.5% from Q1 FY27's ₹705.05 Cr, while PAT fell 32.7% QoQ and OPM dropped from 15.35% — a seasonal step-down (Q1 is the peak summer season for footwear) rather than a trend reversal, and QoQ figures should not be read as a deterioration signal on their own.
Q2 FY-2027 vs prior quarters
The compression is broad-based on costs: material costs rose 13.1% YoY, employee expense 15.3%, other expenses 14.1% and finance costs 18.6% — all outpacing the 11.6% revenue growth. The finance-cost and depreciation increases trace to EBO expansion (right-of-use assets up to ₹411.92 Cr from ₹390 Cr at FY26-end), a strategic driver management itself flagged on the Q4 FY26 call. That call had targeted OPM improvement of over 100bps versus FY26's 13.8% average; instead, Q2 FY27 OPM of 12.15% sits below both the FY26 base and the prior-year quarter, so management's own margin guidance has been missed this quarter, even as the revenue-growth leg of that guidance (supported by price hikes) came through.
The stock went into the print at ₹294.55, down 1.9% over the past month of trading.
What the summary numbers don't show
H1 FY27: revenue ₹1,406.67 Cr (+9.6% YoY), PAT ₹91.89 Cr (+8.0% YoY) — basic EPS ₹1.48 for the quarter vs ₹1.46 YoY and ₹2.21 QoQ.
Management expressed confidence in sustaining Q4 performance in the near term, with an intent to improve operating margins by over 1% compared to FY26's 13.8%. While acknowledging geopolitical uncertainties and potential inflationary pressures, they foresee revenue growth supported by continued price increases and volu
— This quarter: missed
Our pre-result preview had flagged revenue of ₹700–750 Cr, EBITDA growth of 8–9% and net-margin resilience as the gauges to watch; revenue landed at the low end (₹701.62 Cr, in line), but EBITDA grew only ~4.6% YoY (₹97.74 Cr vs ₹93.42 Cr) and net margin compressed rather than held — a miss on the two profitability watch items despite the in-line topline. No fresh brokerage consensus for this specific print could be sourced (Q2 FY27 coverage had not yet updated), so this grading rests on our own preview and the company's own guidance. During the quarter the company also signed renewable-energy agreements and announced (post-quarter, Oct 23) a 26% stake in Clean Max MUOI for captive power — a cost initiative whose benefit isn't yet visible in Q2 margins — while ICRA reaffirmed its AA/Stable and A1+ ratings, indicating no credit-quality concern despite the operating-margin miss.
W1
OPM recovery toward management's guided >14.8% (FY26's 13.8% +100bps) — Q2 FY27 ran at 12.15%, ~265bps short.
W2
EBO expansion payoff: right-of-use assets at ₹411.92 Cr are adding lease/depreciation/employee costs now — watch whether premiumization/ASP gains offset this in H2.
W3
Capex pacing versus the ₹180–200 Cr FY27 guidance — H1 capex (PPE + CWIP) was ₹66.50 Cr, implying a H2 ramp is needed to hit the full-year range.
No subsidiary/associate/JV exists (note 5) — standalone is the only statement, consolidated is not applicable; limited-review unaudited figures; no exceptional items; minor ESOP grant (5,03,500 options) during the quarter under Ind AS 102.